Authors: Barlow-Moshav L, Ahimbisibwe G.M, Chappell E, Amuge M.P, Nanduudu A, Kaudha E, Amukele T, Balamusani D, Kafufu6 B, Nimwesiga A, Kityo C, Kekitiinwa R.A, Namwanje R, Kasangaki G, Mulindwa A, Muzorah A.G, Bbuye D, Nolan M, Giaquinto C, Gibb M.D, Ford D, Musoke...
Search
results
Search
ResultsNew findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children – A story by WHO
July 2021
The World Health Organization (WHO), welcomes new findings presented at the International Pediatric HIV Workshop yesterday, on the superiority of dolutegravir (DTG) -based regimens in young children.
‘Because we all have to grow up;’ supporting adolescents to develop core competencies to transition towards managing their HIV independently
Authors: Chloe Lanyon, Janet Seeley, Stella Namukwaya, Victor Musiime, Sara Paparini, Helen Nakyambadde, Christine Matama, Anna Turkova, Sarah Bernays Published in: JIAS Download
ODYSSEY team at Radboud receives the RIHS Societal Award 2020
March 2021
Contributions made by the ODYSSEY trial have not gone unnoticed and as a result, has earned researchers the Radboud Institute for Health Sciences Societal Impact Award.
DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI- BASED ART IN CHILDREN AND ADOLESCENTS
Authors: Anna Turkova for the ODYSSEY/PENTA-20 Trial Team Published in: CROI 2021 Download
ODYSSEY trial finds new drug is better for treating children living with HIV
March 2021
The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented at the Conference
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al et al. The ODYSSEY Trial TeamPublished in: BMC Infectious Diseases. Download
New European-African Project that will develop UNIVERSAL treatments for children living with HIV
UNIVERSAL, the newly funded European-African clinical research partnership will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing...
EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir
January, 2021
On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe.
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
Authors: Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C,...

